Aripiprazole Lauroxil · Aristada, Aristada Initio

What is Aripiprazole Lauroxil?

Aripiprazole lauroxil is a prodrug of aripiprazole, converted after intramuscular injection to aripiprazole. Aripiprazole acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and as an antagonist at serotonin 5-HT2A receptors. It is studied in schizophrenia, schizoaffective disorder (depressive type) and schizophreniform disorder.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Aristada, Aristada Initio, ALKS-9072, ALKS-9070, AL-NCD

Drug type

Small molecule

Targets

dopamine D2 receptor (DRD2), serotonin 5-HT1A receptor (HTR1A), serotonin 5-HT2A receptor (HTR2A)

Mechanism

Modulator of dopamine D2 receptor (DRD2), serotonin 5-HT1A receptor (HTR1A) and serotonin 5-HT2A receptor (HTR2A)

Pathways

dopamine signaling, serotonin signaling

Therapy area

Psychiatry

Developer

Alkermes Inc (ALKS)

FDA status

Approved as Aristada, Aristada Initio (October 5, 2015), NDA207533 · FDA label

UNII

B786J7A343

✅ FDA-approved uses

• Schizophrenia (Aristada)
• Schizophrenia (initiation of Aristada, in combination with oral aripiprazole) (Aristada Initio)

From the indications section of the FDA label (version of Jan 28, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Schizoaffective Disorder, Depressive TypeSchizophreniaSchizophreniform Disorder

Other drugs acting on DRD2 / HTR1A / HTR2A

More from Alkermes

Sources

• FDA label (DailyMed)
• FDA label Aristada (2025-01-28), indications
• FDA label Aristada Initio (2025-01-28), indications
• ClinicalTrials.gov NCT04203056
• ClinicalTrials.gov NCT04203056
• ClinicalTrials.gov NCT05662306

Updated Oct 11, 2026. Something wrong or missing? Report it on the ALKS page.